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Obesity has emerged as one of the most burdensome conditions in modern society. 
In  this context, understanding the mechanisms controlling food intake is critical. 
At   present, the adipocyte-derived hormone leptin and the pancreatic β-cell-derived 
hormone insulin are considered the principal anorexigenic hormones. Although leptin 
and insulin signal transduction pathways are distinct, their regulation of body weight 
maintenance is concerted. Resistance to the central actions of leptin or insulin is 
linked to the emergence of obesity and diabetes mellitus. A growing body of evidence 
suggests a convergence of leptin and insulin intracellular signaling at the insulin–
receptor–substrate–phosphatidylinositol-3-kinase level. Moreover, numerous factors 
mediating the pathophysiology of leptin resistance, a hallmark of obesity, such as 
endoplasmic reticulum stress, protein tyrosine phosphatase 1B, and suppressor of 
cytokine signaling 3 also contribute to insulin resistance. Recent studies have also 
indicated that insulin potentiates leptin-induced signaling. Thus, a greater understand-
ing of the overlapping functions of leptin and insulin in the central nervous system is 
vital to understand the associated physiological and pathophysiological states. This 
mini-review focuses on the cross talk and integrative signaling of leptin and insulin in 
the regulation of energy homeostasis in the brain.
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LePTin
Since its discovery in 1994 (1), the 16 kDa adipocyte-derived hormone leptin has attracted interest in 
the field of obesity research due to its role in the regulation of energy balance (1–3). Leptin, secreted 
from adipose tissues in proportion to the fat store (4), acts in the hypothalamus to regulate feeding 
behavior (1–3). Leptin receptors (ObR) exist as six different isoforms (ObRa–ObRf), classified as 
short (ObRa, ObRc, OBRd, and ObRf), long (ObRb), and secreted (ObRe) isoforms (5, 6) (Figure 1). 
ObRa, ObRb, ObRc, ObRd, and ObRe were reported to be expressed in mice (6) and ObRa, ObRb, 
ObRc, ObRf (7), and ObRe (8) in rats. In humans, expression of ObRa, ObRb, ObRc (9), and ObRe 
(10) has been described. ObRa, ObRb, ObRc, ObRd, and ObRf isoforms are transmembrane recep-
tors that share the characteristic of possessing a box 1 motif-binding Janus kinase 2 (JAK2). ObRe 
is the only isoform of the leptin receptor lacking a transmembrane domain (10–12). ObRb, the only 
isoform featuring a full-length intracellular domain for interaction with other proteins functioning 
as intracellular signal transducers, is considered the main functional receptor of leptin (13, 14), while 
FiGURe 1 | Structure of leptin receptor isoforms. Six different spliced 
isoforms of the leptin receptors (ObR) have been documented as ObRa–ObRf. 
All the isoforms share identical extracellular binding domain. ObRb possesses 
the longest intracellular domain, which is important for leptin signaling.
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the roles of the other isoforms remain to be elucidated (10, 15). 
ObRb expression is very high in the hypothalamus, where its role 
is well known in mediating body weight regulation. ObRb is a 
member of the class I cytokine receptor family, which mediates 
the Janus kinase signal transducer and activator of transcription 
(JAK-STAT) pathway (16). By binding to ObRb, leptin activates 
multiple signaling cascades, such as JAK2–STAT3 (14), mitogen-
activated protein kinase/extracellular signal-regulated kinase 
(MAPK/ERK) (17, 18), and phosphatidylinositol 3-kinase/pro-
tein kinase B (PI3K/Akt) pathways (19). The major anti-obesity 
effects of leptin are initiated by the phosphorylation of JAK2. The 
activation of JAK2 permits STAT3 phosphorylation and nuclear 
translocation. Nuclear phospho-STAT3 acts as a transcription 
factor for STAT3-targeted genes (20, 21).
Although leptin has been considered a candidate for com-
bating obesity, leptin insensitivity represents the barrier to its 
proper function in obese subjects. Consequently, identifying 
the mechanisms by which leptin resistance develops is critical. 
Impairment of leptin signaling is thought to be one such mecha-
nism. Suppressor of cytokine signaling 3 (SOCS3), a mediator of 
negative feedback to STAT3, is known to attenuate leptin-induced 
signaling, hence SOCS3-deficient mice displayed increased 
leptin-induced STAT3 phosphorylation in the hypothalamus 
(22). Similarly, protein tyrosine phosphatase 1B (PTP1B) dephos-
phorylates JAK2, thereby inhibiting leptin activity. Consistent 
with this action, deactivation of PTP1B results in a decrease in 
body weight and adiposity, and an increase in energy expenditure 
in mice (23). Thus, SOCS3 and PTP1B are molecular mediators 
of leptin resistance.
inSULin
The pancreatic hormone insulin is widely known to reduce 
blood glucose levels via stimulation of glucose uptake by periph-
eral tissues, such as fat, the liver, and skeletal muscle. Insulin 
signaling is initiated through its binding with and mediation 
of protein kinase activity in the beta subunit of the insulin 
receptor (IR) (24). This stimulation permits phosphorylation of 
the insulin receptor substrate (IRS) to promote the activation 
of the PI3K–Akt pathway, which is a major metabolic pathway 
of insulin (25).
In addition to its peripheral actions, insulin enters the brain 
from the circulation (26). Insulin in the central nervous system 
(CNS) affects feeding behavior and energy homeostasis (27–29). 
Several entry pathways of peripheral insulin into the brain have 
been reported (30, 31). These include the transport of insulin by 
brain micovascular endothelial cells from peripheral vessels and 
the delivery of insulin to cerebrospinal fluid (CSF) via choroid 
plexus (30–33). In vivo studies have shown the injection of insulin 
(34) or an insulin-mimetic compound (35) intracerebroventricu-
larly (icv) to reduce food intake in rats. In a similar way of its 
expression in periphery, IR is expressed in the brain (36). The 
hypothalamic signaling pathway of insulin activates IRS–PI3K, 
resulting in the activation of its downstream target protein Akt. 
Insulin-induced Akt activation elicits Akt’s phosphorylation 
of the transcription factor forkhead box protein 1 (FoxO1) to 
suppress the expression of orexigenic neuropeptides (37). This 
insulin-activated PI3K–Akt pathway may be linked to anorexia, 
as the administration of PI3K inhibitors has been shown to hinder 
the effect of insulin on lowering food intake (38).
THe MeCHAniSMS OF LePTin AnD 
inSULin ReSiSTAnCe
A number of mechanisms have been proposed to explain leptin 
and insulin resistance. These include alteration of leptin and 
insulin transport across the blood–brain barrier (BBB) (39, 40), 
alteration of their intracellular signal transduction [e.g., SOCS3, 
PTP1B, and endoplasmic reticulum (ER) stress] (22, 23, 41–45), 
and other such abnormalities. In this part, we will focus on the 
mechanisms-mediated disruption of leptin and insulin signal 
transduction.
Endoplasmic reticulum stress is one of the mechanisms 
involved in defective action of leptin and insulin signaling. The 
ER, an organelle fulfilling diverse cellular functions, plays critical 
roles in the folding and quality control of proteins. Accumulation 
of unfolded or misfolded proteins in the ER disrupts ER homeo-
stasis, which in turn causes ER stress. In reaction to this ER 
stress, cells trigger an adaptive response termed the “unfolded 
protein response” (UPR). To restore normalcy in ER function, 
UPR serves to downregulate protein translation, upregulate 
several chaperone proteins, and activate degradation pathways 
to clear the unfolded or misfolded protein from the ER (46–49). 
ER stress is implicated in a wide range of diseases, including 
metabolic diseases (50), neurodegenerative diseases (51), and 
cancers (52). Obesity is associated with the activation of inflam-
matory pathways and stress response signaling. In the obesity 
model, fat secretes various cytokines (53) and free fatty acids 
(FFAs) (54). These factors were suggested to cause ER stress (55). 
Supporting this theory, the pro-inflammatory cytokines TNFα 
(56), IL-1β (57), and interferon-γ (58) were shown to induce 
ER stress. Current evidence suggests that overnutrition may 
contribute to the development of ER stress and the activation 
FiGURe 2 | A diagrammatic representation of the integration of leptin and insulin signals in the regulation of energy homeostasis in the central 
nervous system. Adipocyte-derived hormone leptin and pancreatic hormone insulin bind to leptin receptors (ObRb) and insulin receptors (IRs), respectively, in the 
hypothalamus. Leptin and insulin regulate the expression of proopiomelanocortin (POMC) and neuropeptide Y (NPY) neurons in the hypothalamus via the 
phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathway to suppress food intake.
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of the UPR signaling pathway (59, 60). For  instance, excess 
dietary saturated fatty acids (SFAs) consumption induces ER 
stress markers (61). Sensitivity to leptin and insulin is reduced 
in obese rats (62, 63). Others and we have reported that ER 
stress is an underlying mechanism mediating leptin resistance 
(43–45). Insulin resistance is also a hallmark of obesity and type 
2 diabetes, and ER stress is known to induce insulin resistance 
by impairing IR signaling (64). Furthermore, ER stress is known 
to induce beta cell death, consequently, compromising insulin 
release (60). ER stress may therefore play a key role in leptin and 
insulin resistance.
Another mediator implicated in the attenuation of leptin and 
insulin signaling is PTP1B. PTP1B is involved in the negative 
regulation of both leptin and insulin signaling (65, 66). PTP1B 
inhibits leptin and insulin activities via dephosphorylation of 
JAK2 (67) and the activated insulin receptor (42), respectively. In 
this regard, PTP1B knockout mice increases sensitivity to leptin 
and insulin, and are resistant to a high-fat diet-induced obesity 
(42, 68). Therefore, development of potent and specific inhibitors 
for PTP1B has become interest in the treatment of type 2 diabetes 
and obesity (69). Over the last decades, diverse PTP1B inhibitors 
have been developed (70–72).
Besides PTP1B, SOCS3 is another negative regulator of leptin 
and insulin signaling. SOCS3 inhibits leptin- and insulin-induced 
signal transduction (41, 73, 74). Deletion of SOCS3 in hypotha-
lamic neurons enhances leptin sensitivity, reduces appetite, and 
protects from diet-induced obesity (75); while overexpression of 
SOCS3 in proopiomelanocortin (POMC) neurons leads to hyper-
phagia and obesity (76, 77). In addition, SOCS3 knockout mice 
show improvement in glucose tolerance and insulin sensitivity 
(78). Based on these evidences, molecules that intervene SOCS3 
actions would represent a potential therapeutic target in the treat-
ment of obesity and type 2 diabetes.
POSSiBLe inTeRACTiOn OF LePTin AnD 
inSULin ACTiviTY in THe CnS
Leptin and insulin induce the JAK–STAT3 and PI3K–Akt path-
ways, respectively, in hypothalamic neurons. Although leptin and 
insulin mediate distinct and common signaling pathways, they 
are both documented as major regulators of energy homeostasis 
and adiposity. It has been indicated that the disruption of IRs 
in the brain may cause obesity, insulin resistance, hyperphagia, 
and hyperleptinemia in mice (79). Moreover, an increase in food 
intake and obesity was observed in IRS-2-deficient mice despite 
their high circulating levels of leptin (80). These findings highlight 
the probable role of insulin in the control of food intake.
Leptin and insulin receptors (IRs) expressed in the CNS 
mediate the anorexigenic effects of these hormones (81–83). 
The hypothalamus is the principal site where leptin and insulin 
exert their regulatory effects on the maintenance of energy 
homeostasis (Figure 2). Leptin and insulin suppress the activity 
of the orexigenic neuropeptide Y (NPY)/agouti-related protein 
(AgRP) neurons, while they stimulate the anorexigenic POMC/
4Thon et al. Leptin and Insulin Signaling in CNS
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cocaine- and amphetamine-related transcript (CART) neurons 
(84, 85) (Figure 2). Additionally, recent studies have elucidated 
the effects of leptin and insulin on each other’s actions in the body. 
For instance, leptin resistance can lead to the inhibition of insulin 
signaling, while insulin resistance can alter leptin signaling in a 
hypothalamic cell line (86). Conversely, our study revealed that 
insulin can potentiate leptin-induced STAT3, a transcription 
factor critical to a major signaling pathway exerting anti-obesity 
effects of leptin (87). Thus, it is possible that leptin and insulin 
may act synergistically to reduce body weight and food intake. 
If this is the case, cross talk between leptin and insulin would be 
crucial to the regulation of whole body energy homeostasis.
ObRb and IR share an aspect of their signaling pathways, 
namely the involvement of PI3K, suggesting that perhaps the 
IRS–PI3K interaction is a mechanism by which the regulatory 
effects of both leptin and insulin on the reduction of food intake 
are integrated (88, 89) (Figure 2). Although the role of leptin-
induced PI3K signaling is not well understood, evidence suggests 
that icv infusion of a PI3K inhibitor interferes with leptin-medi-
ated reduction of food intake (19). Therefore, understanding this 
molecular mediator that links leptin and insulin signaling in the 
hypothalamus may be critical to understanding the regulation of 
energy homeostasis.
Recent literatures have focused on the role of FoxO1 in the 
regulation of food intake and energy expenditure. FoxO1 stimu-
lates expression of transcription of orexigenic NPY and AgRP, 
suppresses the transcription of anorexigenic POMC, and blocks 
STAT3 action in POMC and AgRP neurons. Mechanistically, 
the activation of PI3K/Akt signaling pathway by insulin leads to 
phosphorylation of its downstream mediator, FoxO1. Inactivation 
of FoxO1 by its phosphorylation results in its translocation from 
the nucleus to cytoplasm, allowing STAT3 to bind to POMC or 
AgRP promoter (90, 91). IRS/PI3K/Akt axis is crucial for both 
leptin and insulin in the CNS (38, 92). In addition, the deletion 
of FoxO1 in POMC neuron results in weight loss and increases 
leptin sensitivity (93). Based on these evidences, FoxO1 might be 
a mediator of the potential cross talk between leptin and insulin 
in the regulation of food intake.
As mentioned above, SOCS3 and PTP1B are molecules that 
inhibit leptin signaling. Interestingly, SOCS3 and PTP1B also 
serve as regulators of insulin signaling. It has been suggested that 
SOCS3 suppresses IR signaling (41). Conversely, mice lacking 
PTP1B show enhanced insulin sensitivity (42). Therefore, SOCS3 
(94) and/or PTP1B (95, 96) appear to share the suppressive effects 
on leptin and insulin signaling that are commonly seen in obesity.
Endoplasmic reticulum stress contributes to both leptin and 
insulin resistance in obesity. Thus, interventions that alleviate ER 
stress, by, for instance, improving protein folding via increasing 
chaperone capacity, would offer a potential therapeutic approach 
for the amelioration of obesity and ER-stress-related diseases. 
Recent literature proposes the involvement of 78  kDa glucose-
regulated protein (GRP78) in the regulation of whole-body 
insulin sensitivity (97), glucose homeostasis (98), and protection 
against ER stress (99). Moreover, 4-phenylbutyrate (4-BPA), a 
chemical chaperone that enhances protein folding (100), was 
shown to reverse ER-stress-induced leptin resistance (43, 44). 
Furthermore, BPA alleviated FFAs-induced insulin resistance 
and beta cell dysfunction (101). Additionally, ob/ob mice, given 
a chemical chaperone, showed a reduction in ER stress markers, 
and improved insulin sensitivity and glucose homeostasis (99). 
Of note, GRP78 levels can be upregulated by insulin (102) and 
leptin (103) themselves. Based on a growing body of supporting 
evidence, it seems possible that GRP78 might be a candidate for 
therapeutic application, working by contributing to the actions of 
leptin, and insulin in the maintenance of energy homeostasis. On 
the other hand, the small GTPase Rap1 in the CNS has recently 
been identified as a key component in development of high-fat 
diet-induced obesity through ER stress (104). The suppression 
of Rap1 protect against obesity and metabolic disorders through 
the regulation of food intake and maintaining leptin and insulin 
signaling (104). Thus, manipulation of neuronal Rap1 would 
represent a potential therapeutic target for obesity.
In conclusion, the central signaling of leptin and insulin may 
be vital in controlling energy homeostasis via feeding suppres-
sion. Resistance to the actions of leptin or insulin is associated 
with the pathophysiology of obesity and type 2 diabetes. An 
advanced understanding of the physiological and pathophysi-
ological actions of leptin and insulin in the CNS will shed light 
on potential therapeutic interventions for obesity.
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